Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy

Detalles Bibliográficos
Autores principales: Zhou, Yuling, Zeng, Liang, Yang, Nong, Zhang, Yongchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474210/
https://www.ncbi.nlm.nih.gov/pubmed/34589923
http://dx.doi.org/10.1016/j.jtocrr.2020.100010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474210/
https://www.ncbi.nlm.nih.gov/pubmed/34589923
http://dx.doi.org/10.1016/j.jtocrr.2020.100010

Ejemplares similares